Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Cancer Aggressiveness Clear all
Terminated No phase listed Observational

Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer

NCT03256630
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Genomic Health®, Inc.
Industry
Eligibility
Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jun 25, 2026, 11:05 PM EDT
Recruiting Phase 3 Interventional

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

NCT06470243
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Cabazitaxel, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Prednisone
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
174
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 129 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

NCT06085729
View directory record Official record
Conditions
Prostate Cancer
Interventions
ADI-PEG 20, Cabazitaxel, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Recruiting Phase 2 Interventional

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

NCT06738303
View directory record Official record
Conditions
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Cabazitaxel and carboplatin, Lu-PSMA-617
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jun 25, 2026, 11:05 PM EDT
Suspended No phase listed Observational

Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy

NCT05064111
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
TRUS biopsy
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 2 Interventional

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT05005728
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
Combination Product · Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
26
States / cities
Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Active, not recruiting Phase 1 Interventional

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

NCT04388852
View directory record Official record
Conditions
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Ipilimumab, Valemetostat
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

NCT04472338
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older · Male only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Completed No phase listed Observational

Biobank for African American Prostate Cancer Research in Florida

NCT03232411
View directory record Official record
Conditions
Prostate Cancer
Interventions
Questionnaires, Saliva Samples, Tumor Tissue
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
20 Years and older · Male only
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jun 25, 2026, 11:05 PM EDT
Recruiting No phase listed Observational

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer

NCT04052048
View directory record Official record
Conditions
Prostate Cancer Aggressiveness
Interventions
Subtraction Normalized Expression of Phagocytes Blood Test
Diagnostic Test
Lead sponsor
Immunis.AI
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Not listed Early Phase 1 Interventional

Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

NCT03960788
View directory record Official record
Conditions
Cancer of the Prostate, Castration-resistant Prostate Cancer
Interventions
Gadoxetate Sodium
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Jun 25, 2026, 11:05 PM EDT
Active, not recruiting Phase 2 Interventional

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

NCT04592237
View directory record Official record
Conditions
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Cabazitaxel, Carboplatin, Cetrelimab, Niraparib
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Recruiting No phase listed Observational

Prostate Tissue BioBank

NCT06659614
View directory record Official record
Conditions
Prostate Cancer, Genetic Predisposition
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional

Pioneering Advances in Care and Education (PACE)

NCT03397160
View directory record Official record
Conditions
Decision Support Systems, Clinical, Prostate Cancer
Interventions
Decision Support Intervention (DSI)
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Palo Alto, California • San Francisco, California • Sartell, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Jun 25, 2026, 11:05 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Jun 25, 2026, 11:05 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer

NCT01514669
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jun 25, 2026, 11:05 PM EDT
Completed No phase listed Observational

Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer

NCT01780701
View directory record Official record
Conditions
Prostate Cancer
Interventions
Magnetic Resonance Spectroscopy Imaging with rectal probe
Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jun 25, 2026, 11:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

NCT04709276
View directory record Official record
Conditions
Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer
Interventions
Nivolumab, Ipilimumab, Carboplatin, Cabazitaxel
Drug
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Phase 2 Interventional

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

NCT03263650
View directory record Official record
Conditions
Prostate Cancer Aggressiveness, Prostate Carcinoma
Interventions
Cabazitaxel, Carboplatin, Prednisone 5Mg, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional

Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model

NCT02451345
View directory record Official record
Conditions
Prostate Cancer
Interventions
Personalized risk model+website+coaching intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Jun 25, 2026, 11:05 PM EDT